What is it about?

To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.

Featured Image

Why is it important?

Selective serotonin reuptake inhibitors (SSRIs) came onto the market almost 20 years ago and can result sexual dysfunction (SD) in a significant proportion of men who are taking these medications. The reported frequency of SSRI-associated SD varies significantly, from small percentages to >80%. The exact frequency of SSRI-induced SD is not known. One reason is that the prevalence of male SD in the general population is high which makes it difficult to establish a baseline normal sexual function. Approaches to obtaining data on SSRI-emergent SD might be influenced by marketing strategies, and the condition has been under-reported. However, according to existing reports, at least a third of patients taking SSRIs will complain of treatment-emergent SD.


The treatment of SSRI-associated SD been extremely challenging. Other clinical strategies to restore normal sexual function in patients with SSRI-emergent SD, such as waiting for spontaneous resolution of sexual side-effects, and dosage reduction, might not be acceptable. SD is a major cause of noncompliance with antidepressant therapy [39]. Timely diagnosis and treatment of SSRI emergent SD is critical for the patient’s satisfaction, treatment compliance and the quality of life.

Dr Mohammad Reza Safarinejad
University of Medical Sceices

Read the Original

This page is a summary of: The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study, BJU International, August 2010, Wiley, DOI: 10.1111/j.1464-410x.2009.09154.x.
You can read the full text:




The following have contributed to this page